[Immunologic study on patients with head and neck cancer treated with thymopentin associated with surgery, chemotherapy and radiotherapy].
Patients with H&N tumours treated with surgery, chemo- and radiotherapy also underwent an immunologic therapy with timopentina to evaluate clinic and immunologic efficacy during a 1-year follow-up. Twenty-five patients were recorded in this study divided at random into two groups. In group A the patients were administered timopentina (50 mg/3 times per week/6 weeks) subcutaneously in 4 o 5 cycles during the year. Group B were not administered timopentina. The immunologic state was assessed through investigation of the following: Evaluation of PBL and their T and B cell subpopulations Phagocytosis and blastigenesis Surface receptor and soluble receptor of IL2 NK activity IL1 production. The immunologic values of the two groups were correlated against a control group of twenty non-neoplastic patients. Our study revealed a better immunologic conditions at the end of follow-up in patients treated with timopentina compared to the other patients.
Denaro
A
A
Clinica Otorinolaringoiatrica, Università di Catania.
Stivala
F
F
Mazzarino
M C
MC
D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000096:biosynthesis / Q000378:metabolism; D007694:Killer Cells, Natural / Q000378:metabolism; D007822:Laryngeal Neoplasms / Q000532:radiotherapy* / Q000601:surgery* / Q000628:therapy*; D007830:Larynx / Q000187:drug effects* / Q000528:radiation effects* / Q000601:surgery*; D008213:Lymphocyte Activation; D009303:Nasopharyngeal Neoplasms / Q000532:radiotherapy* / Q000601:surgery* / Q000628:therapy*; D009305:Nasopharynx / Q000187:drug effects* / Q000528:radiation effects* / Q000601:surgery*; D009959:Oropharyngeal Neoplasms / Q000532:radiotherapy* / Q000601:surgery* / Q000628:therapy*; D009960:Oropharynx / Q000187:drug effects* / Q000528:radiation effects* / Q000601:surgery*; D010587:Phagocytosis; D013601:T-Lymphocytes; D016305:Thymopentin / Q000494:pharmacology* / Q000627:therapeutic use*
D007376:Interleukin-2; D016305:Thymopentin
Studio immunologico di pazienti con neoplasie ORL trattati con timopentina con terapia adiuvante la chirurgia, la chemioterapia e la radioterapia.